CSIMarket Company Name, Ticker, Industry, else..


Collegium Pharmaceutical inc   (COLL)
Other Ticker:  
 


 

Collegium Pharmaceutical inc

COLL's Financial Statements and Analysis



Collegium Pharmaceutical inc reported in the third quarter of 2024 net earnings per share of $0.27 a decrease by -49.06 % year on year from $0.53 and decline of -48.08 % from $0.52 earned in II. Quarter (Jun 30 2024).


third quarter of 2024
Earnings Per Share Revenues
$ 0.27 $  159 Mill
$-0.26     -49.06 % $+22M     +16.49 %



Collegium Pharmaceutical Inc 's Revenue rose by 16.49 % in third quarter of 2024 (Sep 30 2024) year on year, to $159 million and advanced by 9.66 % sequentially.


Collegium Pharmaceutical Inc is

More on COLL's Income Statement



Collegium Pharmaceutical Inc 's net income of $9.335 million in the third quarter of 2024 decreased by -54.76 % from net earnings of $20.634 million achieved in III. Quarter a year ago.

Sequentially net earnings fell by -52.39 % from net income of $19.606 million realized in previous quarter.

More on COLL's Growth

Collegium Pharmaceutical Inc Inventories
Inventories grew by 11.45 % to $38 million from III. Quarter a year ago, sequentially inventories rose by 36.5 %. In Sep 30 2024 company's net cash and cash equivalents decreased by $-109 million, capital expenditures fell by -0.065275.38%, to $0 millions compare to same quarter a year ago

More on COLL's Cash flow Statement


Collegium Pharmaceutical inc does not pay out common stock dividend.

In trailing twelve-month period Collegium Pharmaceutical inc earned $ 4.82 cash per share, on a free-cash flow basis 231.83 % of net earning per share.

Book value grew by 8.76 % sequentially to $5.83 per share, 76.1% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value fell to $ -21.38 per share from $ -6.68.

Company repurchased 0.22 million shares or 0.55 % in Sep 30 2024.
Interest Coverage Ratio was 4.5. Debt Coverage Ratio was 0.24.

• More on COLL's Dividends

 Market Capitalization (Millions) 1,204
 Shares Outstanding (Millions) 40
 Total Debt (Millions $) 867
 Revenue (TTM) (Millions $) 452
 Net Income (TTM) (Millions $) 89
 Cash Flow (TTM) (Millions $) -195
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 337




Collegium Pharmaceutical inc does not pay out common stock dividend.

In trailing twelve-month period Collegium Pharmaceutical inc had $ 4.82 cash flow per share, on a free-cash flow basis 231.83 % of net earning per share.

Book value grew by 8.76 % sequentially to $5.83 per share, 76.1% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value fell to $ -21.38 per share from $ -6.68.

Company repurchased 0.22 million shares or 0.55 % in Sep 30 2024.
Interest Coverage Ratio was 4.5. Debt Coverage Ratio was 0.24.

• More on COLL's Balance Sheets

 Market Capitalization (Millions) 1,204
 Shares Outstanding (Millions) 40
 Total Debt (Millions $) 867
 Revenue (TTM) (Millions $) 452
 Net Income (TTM) (Millions $) 89
 Cash Flow (TTM) (Millions $) -195
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 337
   


  News about Collegium Pharmaceutical inc Earnings

Collegium Pharmaceutical Inc Faces Revenue Decline Amidst Market Challenges



Collegium Pharmaceutical Inc, a leading specialty pharmaceutical company, has been facing difficulties in maintaining profitability and sustaining revenue growth in recent times. Despite posting a modest increase in earnings per share (EPS) for the fiscal period ending March 31, 2024, the company experienced a decline in revenue compared to the previous year. Additionally, the authorized generic agreement with Hikma Pharmaceuticals USA Inc., seen as a potential solution, may not be enough to alleviate the company's struggles. This article aims to dissect the situation and shed light on the bearish sentiment surrounding Collegium Pharmaceutical Inc.
Revenue Decline and Market Challenges
In t...

Collegium Pharmaceutical Inc's Positive Momentum Overshadowed by Alarming Revenue Decline

Collegium Pharmaceutical Inc seems to be on a positive trajectory with their recent announcement of a $25 million Accelerated Share Repurchase program. However, despite this positive development, there are several concerning factors that investors should take into consideration.
First and foremost, while the company did achieve positive earnings of $0.58 per share in the October to December 31 2023 time-frame, it's important to note that this is only a marginal improvement from the previous financial reporting period. Additionally, the revenue for the same time-frame saw a dramatic decrease of -95.117% compared to the previous year. This significant drop in revenue raises red flags about the company's ab...

Collegium Pharmaceutical Inc Skyrockets with Impressive 7.321% Revenue Growth in Q3 2023

In the third quarter of 2023, Collegium Pharmaceutical Inc experienced significant growth in revenue and earnings compared to the previous year. According to the company's financial report, revenue increased by 7.321% to $136.31 million, up from $127.01 million in the same quarter last year. Additionally, the company's earnings grew by an impressive 5200% to $0.53 per share, compared to $0.01 per share in the prior year quarter.
Collegium Pharmaceutical Inc's strong performance in revenue is notable, as it outperformed its industry peers who expressed a growth rate of only 1.86% during the same period. This indicates that the company has a competitive edge in the Major Pharmaceutical Preparations industr...

Collegium Pharmaceutical Inc Reports Profitability with $0.34 EPS in Q2 2023, Despite 30.764% Revenue Drop

Collegium Pharmaceutical Inc Sees Improved Profits and Margins, but Faces Revenue Decline
Collegium Pharmaceutical Inc, a major player in the pharmaceutical preparations industry, has reported positive financial results for the second quarter of 2023. The company's earnings per share (EPS) turned around from a loss of $0.15 per share in the same quarter a year prior to a profit of $0.34 per share. Additionally, the company's quarterly net income improved significantly, reaching $13.007 million compared to a net loss of $-5.191 million in the previous year.
One of the key highlights for Collegium Pharmaceutical Inc is its improving profit margins. The company's net margin rose to 9.65% in the April to...

Collegium Pharmaceutical Inc. Reports Impressive 21.647% Revenue Increase in Recent Fiscal Period

Investors in the stock market are always on the lookout for promising companies that have the potential for growth and success. One such company that has caught the attention of many investors lately is Collegium Pharmaceutical Inc., a pharmaceutical company that has been recording some impressive revenue growth despite a net loss in the past fiscal period.
During the 12 months ending in the first quarter of 2023, Collegium Pharmaceutical Inc recorded a cumulative net loss of $-29 million, and the negative return on equity was -15.26%. However, it is important to note that within the major pharmaceutical preparations industry, ther...


Date modified: 2024-11-10T07:13:56+00:00





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com